DDInter94 DDInter927
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Anakinra {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denileukin diftitox
Anakinra {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Anakinra {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Anakinra may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Denileukin diftitox
Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Anakinra may lead to a major life threatening interaction when taken with Etanercept